title: Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.
abstract: Associations of Epstein-Barr virus (EBV) and autoimmune diseases have been hypothesized. We have analysed IgG antibodies to EBV nuclear antigen (EBNA)-2 in sera from Japanese patients with autoimmune systemic connective tissue diseases (CTD), exemplified by systemic lupus erythematosus (SLE), primary Sjogren's syndrome (SS), rheumatoid arthritis (RA), systemic sclerosis (SSc) and secondary SS (classical CTDs complicated with SS). An enzyme-linked immunosorbent assay (ELISA) which uses glutathione-S-transferase polypeptides fused to EBV nuclear antigen (EBNA)-2 and EBNA-1 was developed. Ratios of IgG antibody reactivity to whole IgG concentrations of sera were calculated to normalize EBNA-2 and EBNA-1 antibody levels to the hypergammaglobulinaemia that occurs in CTD. The ELISA optical density OD(450) readings of IgG antibodies to both the amino-terminal aa 1-116 of EBNA-2 and carboxyl-terminal aa 451-641 of EBNA-1 were elevated significantly in patients with SLE, primary SS, RA, SSc and secondary SS when compared to EBNA-1. The OD readings were divided by serum IgG concentrations to normalize for the hypergammaglobulinaemia. The specific levels of IgG antibodies to the amino-terminal region of EBNA-2 were elevated in patients with SLE, primary SS or RA, as well as those with secondary SS complicated with SLE or RA. The EBNA-2 amino-terminal region contains a polyproline tract and a proline-rich sequence and has considerable amino acid sequence homology with many cellular proline-rich proteins. High ratios of EBNA-2 aa 1-116 to EBNA-1 aa 451-641 IgG antibody levels which probably suggest reactivation of EBV latent infection were associated significantly with pulmonary involvement in SS patients. These results are consistent with the hypothesis that the sequence similarity between the amino-terminal region of EBNA-2 and proline-rich cellular proteins is associated with pathogenesis in a subpopulation of CTD patients, possibly by the molecular mimicry-epitope shift mechanism.
authors.affiliation: Herpesvirus Laboratory, Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yamazaki
authors.forename: R
authors.initials: R
authors.lastname: Kitamura
authors.forename: S
authors.initials: S
authors.lastname: Kusano
authors.forename: H
authors.initials: H
authors.lastname: Eda
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Okawa-Takatsuji
authors.forename: S
authors.initials: S
authors.lastname: Aotsuka
authors.forename: K
authors.initials: K
authors.lastname: Yanagi
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000821:virology; D016022:Case-Control Studies; D003240:Connective Tissue Diseases / Q000276:immunology* / Q000821:virology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D020031:Epstein-Barr Virus Infections / Q000276:immunology; D019309:Epstein-Barr Virus Nuclear Antigens / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008168:Lung / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000821:virology; D012859:Sjogren's Syndrome / Q000276:immunology / Q000821:virology; D018709:Statistics, Nonparametric; D014764:Viral Proteins; D017735:Virus Latency
chemical_list: D000914:Antibodies, Viral; C402641:EBNA-2 protein, Human herpesvirus 4; D019309:Epstein-Barr Virus Nuclear Antigens; D007074:Immunoglobulin G; D014764:Viral Proteins
references.citation: Arthritis Rheum. 1999 Dec;42(12):2569-76
references.pmid: 10616002
references.citation: Arthritis Rheum. 1990 Jul;33(7):993-1000
references.pmid: 2164400
references.citation: J Rheumatol. 2000 Apr;27(4):866-73
references.pmid: 10782808
references.citation: Arch Immunol Ther Exp (Warsz). 2000;48(5):347-51
references.pmid: 11140461
references.citation: Arthritis Rheum. 2001 May;44(5):1122-6
references.pmid: 11352244
references.citation: Adv Virus Res. 2001;56:199-217
references.pmid: 11450300
references.citation: Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304
references.pmid: 11790668
references.citation: J Mol Med (Berl). 2001 Dec;79(12):722-31
references.pmid: 11862315
references.citation: Nat Rev Immunol. 2002 Feb;2(2):85-95
references.pmid: 11910899
references.citation: Scand J Rheumatol Suppl. 2002;116:23-7
references.pmid: 12109539
references.citation: Arthritis Rheum. 2002 Jul;46(7):1866-72
references.pmid: 12124871
references.citation: J Virol. 2003 Mar;77(6):3824-31
references.pmid: 12610157
references.citation: Clin Diagn Lab Immunol. 2004 Jan;11(1):123-30
references.pmid: 14715558
references.citation: Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1033-8
references.pmid: 14732686
references.citation: N Engl J Med. 1975 Feb 20;292(8):403-7
references.pmid: 1089199
references.citation: N Engl J Med. 1975 Feb 13;292(7):344-7
references.pmid: 1090839
references.citation: Chest. 1976 Sep;70(03):354-61
references.pmid: 989035
references.citation: Lancet. 1979 Mar 10;1(8115):549
references.pmid: 85124
references.citation: Arthritis Rheum. 1980 May;23(5):581-90
references.pmid: 7378088
references.citation: Arthritis Rheum. 1982 Nov;25(11):1271-7
references.pmid: 7138600
references.citation: Nature. 1984 Jul 19-25;310(5974):207-11
references.pmid: 6087149
references.citation: J Virol. 1984 Oct;52(1):88-93
references.pmid: 6090712
references.citation: J Immunol. 1985 Jan;134(1):211-6
references.pmid: 2981091
references.citation: Proc Natl Acad Sci U S A. 1985 Sep;82(18):6300-4
references.pmid: 2412231
references.citation: J Clin Invest. 1986 May;77(5):1539-47
references.pmid: 2422209
references.citation: J Gen Virol. 1986 Oct;67 ( Pt 10):2253-8
references.pmid: 3020161
references.citation: J Rheumatol. 1990 Nov;17(11):1442-9
references.pmid: 2177109
references.citation: J Infect Dis. 1991 Jul;164(1):22-8
references.pmid: 1647426
references.citation: J Clin Microbiol. 1992 Jun;30(6):1442-8
references.pmid: 1320628
references.citation: Arthritis Rheum. 1993 Mar;36(3):340-7
references.pmid: 8452579
references.citation: J Rheumatol. 1993 May;20(5):831-7
references.pmid: 8336308
references.citation: Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12010-4
references.pmid: 8265662
references.citation: J Exp Med. 1995 Feb 1;181(2):453-61
references.pmid: 7530756
references.citation: J Exp Med. 1995 Jul 1;182(1):75-85
references.pmid: 7540658
references.citation: J Immunol. 1996 May 1;156(9):3480-5
references.pmid: 8617976
references.citation: J Rheumatol. 1996 Jun;23(6):1088-94
references.pmid: 8782145
references.citation: J Exp Med. 1996 Nov 1;184(5):1791-800
references.pmid: 8920867
references.citation: Nucleic Acids Res. 1997 Sep 1;25(17):3389-402
references.pmid: 9254694
references.citation: J Rheumatol. 1997 Nov;24(11):2090-6
references.pmid: 9375865
references.citation: J Clin Invest. 1997 Dec 15;100(12):3019-26
references.pmid: 9399948
references.citation: Clin Exp Rheumatol. 1998 May-Jun;16(3):289-94
references.pmid: 9631751
references.citation: Rev Rhum Engl Ed. 1998 Jun;65(6):365-8
references.pmid: 9670326
references.citation: Clin Exp Rheumatol. 1998 Jul-Aug;16(4):409-15
references.pmid: 9706420
references.citation: Immunol Rev. 1998 Aug;164:93-100
references.pmid: 9795767
references.citation: Immunol Rev. 1998 Aug;164:185-200
references.pmid: 9795776
references.citation: J Autoimmun. 1998 Oct;11(5):431-8
references.pmid: 9802926
references.citation: J Immunol. 1999 Mar 15;162(6):3694-701
references.pmid: 10092832
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5164-8
references.pmid: 10220436
references.citation: Autoimmunity. 1999;30(1):53-9
references.pmid: 10433095
references.citation: J Immunol. 1986 Nov 15;137(10):3162-8
references.pmid: 3021847
references.citation: J Immunol. 1987 Jan 15;138(2):593-9
references.pmid: 2432130
references.citation: Proc Natl Acad Sci U S A. 1987 Jan;84(2):570-4
references.pmid: 3025881
references.citation: J Exp Med. 1987 Apr 1;165(4):1026-40
references.pmid: 2435830
references.citation: Br J Rheumatol. 1987 Jun;26(3):193-6
references.pmid: 3034370
references.citation: J Rheumatol Suppl. 1987 Jun;14 Suppl 13:112-7
references.pmid: 2441042
references.citation: Cell. 1987 Sep 11;50(6):819-20
references.pmid: 3621346
references.citation: Int J Cancer. 1987 Sep 15;40(3):349-53
references.pmid: 3040599
references.citation: J Virol. 1988 Jan;62(1):100-5
references.pmid: 2446012
references.citation: Rheum Dis Clin North Am. 1987 Aug;13(2):275-92
references.pmid: 2827246
references.citation: Arthritis Rheum. 1988 Mar;31(3):315-24
references.pmid: 3358796
references.citation: Ann N Y Acad Sci. 1988;540:210-7
references.pmid: 2462803
references.citation: Int J Cancer. 1989 Jun 15;43(6):1017-21
references.pmid: 2543639
references.citation: J Autoimmun. 1989 Jun;2 Suppl:187-94
references.pmid: 2673272
references.citation: Brain. 2000 Mar;123 Pt 3:508-18
references.pmid: 10686174